Evidence map›Paper›PMID 37515185›Full record

ArticleViruses2023

Tumor Necrosis Factor and Interleukin-1β Upregulate NRP2 Expression and Promote SARS-CoV-2 Proliferation.

Michinori Ishitoku, Sho Mokuda, Kei Araki, Hirofumi Watanabe, Hiroki Kohno, Tomohiro Sugimoto, Yusuke Yoshida, Takemasa Sakaguchi, Junya Masumoto, Shintaro Hirata and 1 more

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Article
  3. Molecular mechanisms of SARS-CoV-2 entry: implications for biomedical strategies.Microbiology and molecular biology reviews : MMBR · 2025
    Review
  4. Article
  5. The Functions of SARS-CoV-2 Receptors in Diabetes-Related Severe COVID-19.International journal of molecular sciences · 2024
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Michinori IshitokuDepartment of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima 734-8551, Japan.
Sho MokudaDepartment of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima 734-8551, Japan.ORCID 0000-0002-8529-1016
Kei ArakiDepartment of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima 734-8551, Japan.
Hirofumi WatanabeDepartment of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima 734-8551, Japan.
Hiroki KohnoDepartment of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima 734-8551, Japan.ORCID 0000-0003-2947-6216
Tomohiro SugimotoDepartment of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima 734-8551, Japan.
Yusuke YoshidaDepartment of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima 734-8551, Japan.
Takemasa SakaguchiDepartment of Virology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan.ORCID 0000-0002-3754-1252
Junya MasumotoDepartment of Pathology, Ehime University Proteo-Science Center and Graduate School of Medicine, Toon 791-0295, Japan.ORCID 0000-0003-0847-0456
Shintaro HirataDepartment of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima 734-8551, Japan.
Eiji SugiyamaDepartment of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima 734-8551, Japan.
Hiroshima University Hospital · JPEhime University · JPHiroshima University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), utilizes the host receptor angiotensin-converting enzyme 2 (ACE2) and the auxiliary receptor Neuropilin-1 (NRP1) to enter host cells. NRP1 has another isoform, NRP2, whose function in COVID-19 has seldom been reported. In addition, although patients with severe cases of COVID-19 often exhibit increased levels of proinflammatory cytokines, the relationship between these cytokines and SARS-CoV-2 proliferation remains unknown. The aim of this study is to clarify the roles of proinflammatory cytokines in Neuropilin expressions and in SARS-CoV-2 infection. To identify the expression patterns of NRP under inflamed and noninflamed conditions, next-generation sequencing (RNA-seq), immunohistochemistry, quantitative real-time PCR, and Western blotting were performed using primary cultured fibroblast-like synoviocytes, MH7A (immortalized cell line of human rheumatoid fibroblast-like synoviocytes), immortalized MRC5 (human embryonic lung fibroblast), and synovial tissues. To measure viral proliferative capacity, SARS-CoV-2 infection experiments were also performed. NRP2 was upregulated in inflamed tissues. Cytokine-stimulated human fibroblast cell lines, such as MH7A and immortalized MRC5, revealed that NRP2 expression increased with co-stimulation of tumor necrosis factor α (TNFα) and interleukin-1 beta (IL-1β) and was suppressed with anti-TNFα antibody alone. TNFα and IL-1β promoted SARS-CoV-2 proliferation and Spike protein binding. The viral proliferation coincided with the expression of NRP2, which was modulated through plasmid transfections. Our results revealed that proinflammatory cytokines, including TNFα, contribute to NRP2 upregulation and SARS-CoV-2 proliferation in host human cells.

Indexed as

COVID-19SARS-CoV-2Cell ProliferationCytokinesHumansInterleukin-1betaNeuropilin-2Spike Glycoprotein, CoronavirusTumor Necrosis Factor-alphaCytokinesIL1B protein, humanInterleukin-1betaNeuropilin-2neuropilin-2, humanSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2TNF protein, humanTumor Necrosis Factor-alphacoronavirus disease 2019 (COVID-19)Neuropilin-1 (NRP1)Neuropilin-2 (NRP2)severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)tumor necrosis factor alpha (TNFα)

Identifiers

PMID37515185
PMCPMC10383177
OpenAlexW4383069077

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.